(Lymphoma) Is BTK Inhibitor Ibrutinib Monotherapy Effective?

For patients aged 65 and older without 17p chromosome deletion and treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma, an international multi-institution 1:1 randomized controlled study compared Ibrutinib monotherapy versus Chlorambucil (Leukeran). This trial evaluated whether Ibrutinib could provide superior progression-free survival compared to the standard chlorambucil treatment in this elderly patient population.

Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5